A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity

Pharmacogenetics and Genomics

Volumn 20, Issue 6, 2010, Pages 377-388

  Arsenault, Jason ^a   Lehoux, Julie ^a   Lanthier, Luc ^a   Cabana, Jérôme ^a   Guillemette, Gaëtan ^a   Lavigne, Pierre ^a   Leduc, Richard ^a   Escher, Emanuel ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Angiotensin II; EXP3174; HAT1; Hypertension; Losartan; Single nucleotide polymorphism

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALANINE; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; EXP 3171; IRBESARTAN; LOSARTAN; TELMISARTAN; THREONINE; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IC 50; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77952420727     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833a6d4a     Document Type: Article

References (40)

1. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
2. Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007; 115:725-732.
3. Auger-Messier M, Arguin G, Chaloux B, Leduc R, Escher E, Guillemette G. Down-regulation of inositol 1,4,5-trisphosphate receptor in cells stably expressing the constitutively active angiotensin II N111G-AT(1) receptor. Mol Endocrinol 2004; 18:2967-2980.
4. Arsenault J, Renaud MP, Clement M, Fillion D, Guillemette G, Leduc R, et al. Temperature-dependent variations of ligand-receptor contact points in hAT(1). J Pept Sci 2007; 13:575-580.
5. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007; 113:210-226.
6. Yan C, Zhan J, Feng W. Gene polymorphisms of angiotensin II type 1 receptor and angiotensin-converting enzyme in two ethnic groups living in Zhejiang Province, China. J Renin Angiotensin Aldosterone Syst 2005; 6:132-137.
7. 1 receptor. Trends Endocrinol Metab 2003; 14:66-71.
8. 1 receptor antagonists. J Med Chem 2006; 49:1526-1535.
9. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl 1):S73-S86.
10. Association CP. Compendium of Pharmaceuticals and Specialties. 40th edition ed. Ottawa: Canadian Pharmacists Association; 2005.
11. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58:641-649.
12. 1 antagonist. J Pharm Biomed Anal 2002; 28:125-135.
13. 1 angiotensin II receptor antagonists based on the pyrazolo(3,4-b)pyridine and related heteroaromatic bicyclic systems. J Med Chem 2008; 51:2137-2146.
14. Clement M, Martin SS, Beaulieu ME, Chamberland C, Lavigne P, Leduc R, et al. Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay. J Biol Chem 2005; 280:27121-27129.
15. Rihakova L, Deraet M, Auger-Messier M, Perodin J, Boucard AA, Guillemette G, et al. Methionine proximity assay, a novel method for exploring peptide ligand-receptor interaction. J Recept Signal Transduct Res 2002; 22:297-313.
16. 1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994; 269:16533-16536.
17. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270:2284-2289.
18. Antonellis A, Rogus JJ, Canani LH, Makita Y, Pezzolesi MG, Nam M, et al. A method for developing high-density SNP maps and its application at the type 1 angiotensin II receptor (AGTR1) locus. Genomics 2002; 79:326-332.
19. Crawford DC, Carlson CS, Rieder MJ, Carrington DP, Yi Q, Smith JD, et al. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet 2004; 74:610-622.
20. Hansen JL, Haunso S, Brann MR, Sheikh SP, Weiner DM. Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor. Mol Pharmacol 2004; 65:770-777.
21. Gosselin MJ, Leclerc PC, Auger-Messier M, Guillemette G, Escher E, Leduc R. Molecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding. Biochim Biophys Acta 2000; 1497:94-102.
22. 1 receptors. Regul Pept 1995; 59:303-311.
23. Inoue Y, Nakamura N, Inagami T. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997; 15:703-714.
24. Lim J, Kim YJ, Yoon Y, Kim SO, Kang H, Park J, et al. Comparative study of the linkage disequilibrium of an ENCODE region, chromosome 7p15, in Korean, Japanese, and Han Chinese samples. Genomics 2006; 87:392-398.
25. Bosse R, Servant G, Zhou LM, Boulay G, Guillemette G, Escher E. Sar1-p-benzoylphenylalanine-angiotensin, a new photoaffinity probe for selective labeling of the type 2 angiotensin receptor. Regul Pept 1993; 44:215-223.
26. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80:849-857.
27. Perodin J, Deraet M, Auger-Messier M, Boucard AA, Rihakova L, Beaulieu ME, et al. Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor. Biochemistry 2002; 41:14348-14356.
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
29. Blanton MP, Cohen JB. Identifying the lipid-protein interface of the Torpedo nicotinic acetylcholine receptor: secondary structure implications. Biochemistry 1994; 33:2859-2872.
30. 1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006; 49:4305-4316.
31. 1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20:953-970.
32. Integrating ethics and science in the International HapMap Project. Nat Rev Genet 2004; 5:467-475.
33. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81:328-345.
34. 1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003; 46:2261-2270.
35. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
36. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 2003; 23:720-725.
37. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16:497-514.
38. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33 (Suppl 2):23-30.
39. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31:1549-1557.
40. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, et al. Pharmacokinetics of Losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71:89-98.